The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031 [Upcoming Report]

  • Lowest Price Guaranteed From USD 5,499

  • Published
    April 2021

  • Pages
    132

  • View Count
    803

Example Insights

  • In the coming years, the market is anticipated to grow at a significant pace owing to the rising awareness of the disease and increasing interest of stakeholders to invest in this field.
  • More novel therapy solutions are being developed by various industry as well as non-industry stakeholders, which are actively focused on addressing the challenges related to treatment of polycystic ovarian syndrome.
  • The significant impact on market size can also be attributed to the contributions of several big pharma players being actively involved in evaluation of various therapy candidates in this field. 

Overview

The “Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of polycystic ovarian syndrome.

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s drug class, route of administration, type of treatment, regulatory milestones, and other development activities.

One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies for polycystic ovarian syndrome, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of the forecasted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2021-2031.  

Scope of the Report

  • A detailed assessment of the therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, symptoms treated, combination drugs (if available) and line of treatment including all clinical and nonclinical stages.
  • Detailed profiles of the players that are engaged in the development of drug products / therapies for polycystic ovarian syndrome, featuring overview of the company, its financial information (if available), a description of its product portfolio, recent collaborations and an informed future outlook.
  • An insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules (phase II and phase III), taking into consideration size of enrolled patient population, route of administration, treatment type and dosing frequency, and target patient population, expected launch date and size of developer company.
  • A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field. 
  • An insightful analysis of the patents filed / granted for polycystic ovary syndrome, since 2016, taking into consideration various parameters, such as type of patent, publication year, geographical location, type of applicant, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. The chapter also includes a detailed patent benchmarking and an insightful valuation analysis.
  • An in-depth analysis of grants awarded to various research institutes for the projects related to polycystic ovary syndrome, in the period between 2016 and April 2021, on the basis of parameters, such as year of award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, emerging focus areas of the grants, popular NIH departments, and type of recipient organization, while highlighting popular recipient organizations, popular program officers and regional distribution of recipient organizations.  
  • A detailed analysis of completed, ongoing and planned clinical studies, based on the various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, study design, trial recruitment status, and trial focus, highlighting leading sponsors, type of organization, and regional distribution of trials. 

Key Questions Answered

  • What are the prevalent R&D trends related to polycystic ovarian syndrome?
  • What are the key challenges faced by stakeholders engaged in this domain?
  • What are the principal therapies developed by the companies in this domain?
  • Who are the leading industry and non-industry players in this market?
  • What are the contributions of big pharma players in this field?
  • What are the key geographies where research on polycystic ovarian syndrome is being conducted?
  • Which are the leading administering institute centers supporting the research related to this domain?
  • How has the intellectual property landscape in this market evolved over the years?
  • Who are the key opinion leaders / experts in this field?
  • What are the factors that are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Table Of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Pipeline Review
4.1. Chapter Overview
4.2. Polycystic Ovarian Syndrome: Development Pipeline
4.3. Polycystic Ovarian Syndrome: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Drug Class
4.3.3. Analysis by Symptoms Treated
4.3.4. Analysis by Drug Class and Symptoms Treated
4.3.5. Analysis by Line of Treatment
4.3.6. Analysis by Route of Administration

4.4. Polycystic Ovarian Syndrome: Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Geographical Location
4.4.4. Analysis by Type of Player
4.4.5. Analysis by Most Active Players
4.4.6. Analysis by Drug Class

5. Company Profiles

6. KOL Analysis

7. Grants Analysis

8. Clinical Trials Analysis

9. Patent Analysis

10. Market Sizing and Opportunity Analysis

11. Appendix 1: Tabulated Data

12. Appendix 2: List of Companies and Organizations

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com